Dr. Cherry Au
Hematology & Oncology (Hematology & Oncology Physician)
1441 Eastlake Ave
Los Angeles, CA 90089
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- In the NPI registry since
- 2021
- Medicare patients seen, 2024
- 33
Licensed in Illinois since 2024, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2021Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A203137 (first issued 2025; current) -
Internal Medicine Physician
IL license 036170132 (first issued 2024; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 33
- Services billed
- 79
- Patients’ average age
- 72
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 13 companies reported 23 payments worth $942 in total to this clinician.
| Secura Bio, Inc. | $194 |
|---|---|
| Janssen Biotech, Inc. | $161 |
| Alexion Pharmaceuticals, Inc. | $154 |
| Novartis Pharmaceuticals Corporation | $143 |
| Sumitomo Pharma America, Inc. | $51.23 |
| Daiichi Sankyo Inc. | $44.25 |
| Celgene Corporation | $35.28 |
| Genzyme Corporation | $34.98 |
| Food and Beverage | $849 |
|---|---|
| Education | $92.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Oct 10, 2025 | Education SOLIRIS · Rare Disease · in-kind Company’s descriptionTextbook | $92.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.